Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer

This is a small Phase II study testing whether targeted internal radiation treatment (HDREBT) followed by two doses of the immunotherapy drug Nivolumab is safe, practical, and potentially effective before patients undergo surgery (TME) to remove rectal cancer.

NCT Number	NCT07645118
Lead Sponsor	Dr. Te Vuong
Conditions	Locally Advanced Rectal Cancer
Enrollment	10 participants
Start Date	2026-07
Primary Completion	2028-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-12